Ipilimumab

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2025 financial results before the market opens on Monday, August 11, 2025. Agenus will then host a stakeholder briefing in late August to spotlight key strategic plans, data milestones and provide a comprehensive update on the global botensilimab (BOT) and balstilimab (BAL) development program. About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels. About Botensilimab (BOT) Botensilimab (AGEN1181) is a novel, multifunctional, Fc-enhanced CTLA-4 antibody engineered to boost both innate and adaptive anti-tumor immune responses. Its unique design aims to overcome the limitations of first-generation CTLA-4 inhibitors (like ipilimumab) and extend immunotherapy benefits to “cold” tumors that typically respond poorly or not at all to standard immune checkpoint blockade. Botensilimab’s Fc-enhanced structure allows it to robustly engage activating Fc receptors on key immune cells, thereby priming and activating T cells, depleting immunosuppressive regulatory T cells in the tumor microenvironment, activating myeloid cells, and inducing long-term immune memory. Through these mechanisms, botensilimab has demonstrated the ability to ignite immune responses across a range of solid tumors, including those resistant to conventional PD-1 or CTLA-4 therapies. To date, approximately 1,200 patients have been treated with botensilimab and/or balstilimab in Phase 1 and 2 trials. Botensilimab alone or in combination with Agenus’ investigational PD-1 antibody balstilimab has shown clinical responses in nine different metastatic cancers in late-line settings. For more information on ongoing botensilimab trials, please visit www.clinicaltrials.gov. About Balstilimab (BAL) Balstilimab (AGEN2034) is a novel, fully human monoclonal IgG4 antibody that blocks PD-1 (programmed cell death-1) from interacting with its ligands PD-L1 and PD-L2. By inhibiting the PD-1 checkpoint pathway, balstilimab aims to restore T-cell activity against tumors. It has been evaluated in over 900 patients to date and has demonstrated clinical activity with a favorable tolerability profile in several tumor types. Balstilimab is being studied both as a monotherapy and in combination with other agents (such as botensilimab) to expand its therapeutic impact. Forward Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the botensilimab and balstilimab clinical programs, expected trial initiations and regulatory plans, and the potential benefits of the combination therapy. Words such as “may,” “believes,” “expects,” “anticipates,” “hopes,” “intends,” “plans,” “forecasts,” “estimates,” “will,” “potential,” “game-changing,” “curative,” and similar expressions are intended to identify forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. Factors that could cause actual results to differ include, but are not limited to, those described under the “Risk Factors” section of Agenus’ most recent Annual Report on Form 10-K for 2024 and subsequent Quarterly Reports on Form 10-Q filed with the SEC. Agenus cautions investors not to place undue reliance on forward-looking statements in this release, which speak only as of the date of this announcement. The company undertakes no obligation to update or revise these statements, except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Investors 917-362-1370 | investor@agenusbio.com Media 781-674-4422 | communications@agenusbio.com

临床试验病友交流群（点击）一、新药快讯1、免疫治疗双子星欧狄沃联合逸沃获批用于肺癌一线治疗2025年7月28日，PD-1抑制剂纳武利尤单抗（欧狄沃）联合CTLA-4抑制剂伊匹木单抗（逸沃）获批新适应症，适用于PD-L1表达阳性（TPS评分≥1%）的EGFR和ALK阴性的晚期非小细胞肺癌的一线治疗，这是中国首个获批的肺癌双免疫联合疗法，这一适应症是基于一项三期临床试验，22%的患者生存时间超过了6年，同时避免了化疗毒性。欧狄沃联合逸沃的中位缓解持续时间超过2年，达到了24.5个月。2、耶鲁大学开发出新型抗体-RNA疗法，用于胰腺癌、脑癌和黑色素瘤发布在《科学·转化医学》的一项研究表明，一种特殊的抗体TMAB3可以将RNA疗法准确送递至肿瘤内部，在动物模型里显著延长了生存时间。当TMAB3抗体与能激活人体免疫反应的RNA分子结合，注射入血液之后可以精准定位肿瘤，进入肿瘤内并摧毁顽固的癌细胞，而且不影响健康组织，这个疗法适合胰腺癌、髓母细胞瘤、黑色素瘤。3、依沃西单抗挑战替雷利珠单抗成功，获批肺癌新适应症7月28日，依沃西单抗第三项适应症上市申请获得受理，适应症为联合化疗一线治疗晚期鳞状非小细胞肺癌，依沃西单抗是全球首个PD-1和VEGF双抗药物，今年4月获批一线治疗PD-L1阳性的晚期非小细胞肺癌，而这次则是身边肺鳞癌的一线治疗，在临床试验对比中，依沃西单抗联合化疗完胜替雷利珠单抗联合化疗，无进展生存时间获得了决定性胜出的阳性结果。二、抗癌前沿1、来自100万肿瘤患者数据，等待手术时癌细胞能增殖多快最近，一项发布在《乳腺癌》的文献尝试回答一个问题，确诊乳腺癌等待手术期间，体内的癌症会不会失控。研究小组分析了100万例乳腺癌患者的治疗数据发现，直径小于2厘米的肿瘤大概需要2到4天才能长大1毫米，三阴性乳腺癌生长速度较快，大概1.3天生长1毫米，HER2阳性乳腺癌生长较慢，大概5天后会有1毫米的增长。也就是即便是手术延迟一个月，大部分的肿瘤直径也只有几个毫米的增长，不会短期“突飞猛进”的体积暴增。参加抗癌新药临床试验，请关注“癌度”微信公众号，回复数字 “1” 咨询！